|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date22 Dec 2014 |
A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients with Erythropoietic Protoporphyria (EPP). - CUV052
A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients With Erythropoietic Protoporphyria (EPP)
The purpose of this study is to evaluate the concentration of afamelanotide in serum after the administration of afamelanotide in adolescent and adult EPP patients.
/ Not yet recruitingPhase 2 A Phase IIa, Open Label, Proof of Concept Study to Evaluate the Safety of Aqueous Afamelanotide Solution in Patients with acute Arterial Ischaemic Stroke (AIS) who are ineligible for Intravenous Thrombolysis (IVT) or Endovascular Thrombectomy (EVT) - CUV803
100 Clinical Results associated with Clinuvel Europe Ltd.
0 Patents (Medical) associated with Clinuvel Europe Ltd.
100 Deals associated with Clinuvel Europe Ltd.
100 Translational Medicine associated with Clinuvel Europe Ltd.